Bob Bradway, Amgen CEO

#ES­MO22: Am­gen drops the de­tailed deck for KRAS G12C, with erod­ing da­ta like­ly to trig­ger fresh de­bate

PARIS — Am­gen put its best foot for­ward in Paris ear­ly Mon­day, with the news that its KRAS G12C star Lumakras of­fered a sol­id ben­e­fit for pa­tients suf­fer­ing from ad­vanced cas­es of non-small cell lung can­cer com­pared with chemo. The top-line fig­ures in­clud­ed a drop of 34% in the risk of dis­ease pro­gres­sion at 12 months in Code­BreaK 200, the con­fir­ma­to­ry study be­ing used for a near cer­tain full ap­proval.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.